Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's the holidays. Lawyers scratching each other's backs....I'm going to be in Tahoe skiing (with my good friend Kennedy) over Christmas....I'm going to be in Virgin Gorda for the New Year. Hey, let's just postpone this for a month.
The funny part about this is it’s coming from a member of the party of diversity and empowerment, yet, apparently, pharmacists can’t be women.
Like a lump of coal.
So you skipped Sunday School? Santa and that elf will not be happy!
Catholics or convicts?
As Frank Zappa asked... Is that a real poncho . . . I mean
Is that a Mexican poncho or is that a Sears poncho?
My only question is what would JT be using to take our eyes off the ball of the mistakes he and Kennedy made if the AZN v. Teva decision hadn’t dropped in his lap?
You should be on cloud 9. Sleepy and his merry band of green new dealers are about to take over the joint and everything you've hated about the direction of the country for the past four years will come to an end on January 20th. So show some enthusiasm. Oh, and by the way, Amarin will be just fine.
If all the jurors voted for Obama and Biden, we’ll know it’s rigged.
BREAKING NEWS: Hikma Pharmaceuticals announced today that it intends to vigorously defend its rights to sell its generic version of Vascepa.
Amarin management is competing for the congeniality award.
Europe approval will move the PPS into low teens and then a buyout with a 2x multiple and a CVR for US sales bringing ultimate PPS to $33.
And I’ll take Overtown over the Tenderloin any day!
More conspiracy theories!
What it is ain’t exactly clear!
I wonder if his comment about brand Epadel maintaining 60% of market share after nine years (I assume this is nine years after generics entered the market) was an indication that they truly think they have this much opportunity in the good old U.S.A. We all know Mr. Underpromise doesn't throw around comments like this just for something to talk about. So, hmmm!
Pre-market getting all excited about another big Thero earth shattering presentation.
Has anybody asked Elisabeth? Has BB emailed JT to ask him this specific question? Will they answer?
Send Thero's resume to Hikma.
It will be interesting to see if Thero gets any questions on the generic script numbers at Stifel or Jeffries.
Do you honestly think Thero is as gifted as these guys?
Call CVS and ask if they’re stocking it yet.
Amarin needs a CEO that has the ability to promote the company with at least a little bit of carnival barker in him. Going on CNBC and saying "it works" doesn't quite get the job done. The biggest problem they have is fighting the "fish oil" stigma and they need someone who understands that headwind and has the ability to deal with it. JT is not that guy. And this makes this whole slow walking attitude even more aggravating. Waiting and hoping for the world to wake up and realize the promise of Vascepa while they toil away one country at a time. Pathetic.
How many salespeople does HLS have on Vascepa?
I would suggest that Covington wasn’t anal enough!
So, more or less a seat of the pants approach. And I hear Wall Street really likes that!
After the last raise at $18 and the subsequent announcement of an Ad Comm tanking the stock, JT has to be considered toxic. No trust!
I would rather they had figured things out while they were waiting on Reduce it results. BP doesn’t sit around and finish chewing their gum before taking the next step. There is no excuse.
The difference between me and you: JT works for me and you work for JT.
You spend way too much time here.
Trolling JT! A pretty easy target.
"Reaffirmed clinical trial results from study of VASCEPA in China are expected by year end 2020: Assuming positive results from this study conducted by Amarin’s commercial partner for VASCEPA in China, regulatory submission in China could follow promptly thereafter."
JT getting aggressive here. But then again, promptly in his world could mean before the end of 2021. I've never seen anyone in business with such an incredible disregard for the concept of urgency.
JT's narrative has been provided to him by Kennedy. If the company was as confident as the statements would have us believe, they would be providing facts regarding supply issues. The company knows supply is not an issue for the generics, so by not backing up their statements, they have created a Covid restricted stadium full of wiggle room for when they get called out. Shameful.
November investor presentation says Teva can enter the market “soon after an en banc loss”. Not “if”. They know.
You’re assuming that the BOD isn’t part of the problem.
You guys need a Biden!
Berkeley. Pals with Du.
Since he just expressed his feelings about intellectual property, I just might!
Isn't kicking the can down the road Thero's business strategy? Or is that the brainchild of Kennedy, the master strategist? The road ends when there's no more patent or regulatory protection and we'd never know if they actually had a plan to grow the company beyond that point. So, he's clearly milking the crap out of the same milk carton that he's been featured on keeping his paycheck alive until someone calls BS.
Even the milk carton is missing!